{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-047036","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2023-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.677722+00:00","generated_at":"2026-06-10T22:39:32.987300+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"KalVista reports Q1 FY2024 net loss $25.3M; KONFIDENT phase 3 enrollment achieved","bullets":["Net loss $25.3M ($0.74/share) vs $23.0M ($0.94/share) in prior-year quarter.","Cash, equivalents and marketable securities $123.3M vs $149.4M as of April 30, 2023.","Phase 3 KONFIDENT trial for sebetralstat hit enrollment target of 114 patients; data readout on track for Q4 2023.","NDA submission planned for H1 2024; Nicole Sweeny appointed Chief Commercial Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-047036","json":"https://secwatch.observer/filing/0000950170-23-047036.json","markdown":"https://secwatch.observer/filing/0000950170-23-047036.md","text":"https://secwatch.observer/filing/0000950170-23-047036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000095017023047036/0000950170-23-047036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000095017023047036/kalv-20230907.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:39:32.987300+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"018ed79c54e471ed92160025bcf0a605a6a7a11e","claim":"KalVista Pharmaceuticals, Inc. reported the first fiscal quarter ended July 31, 2023 results: net income $25.3 million, or $(0.74) per weighted average basic and diluted share, EPS $(0.74) per weighted average basic and diluted share.","evidence_excerpt":"KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000095017023047036/0000950170-23-047036-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first fiscal quarter ended July 31, 2023"},{"label":"Net income","value":"$25.3 million, or $(0.74) per weighted average basic and diluted share"},{"label":"EPS","value":"$(0.74) per weighted average basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}